Curriculum Vitae

David Micheal Weed, M.D.

Research Affiliations

Offices

Preferred Research Partners, Inc.
11219 Financial Centre Parkway, Suite 320
Little Rock, AR 72211
(501)553-9987 (501)
553-9986 FAX

Preferred Research Partners Arkansas Center for Sleep Medicine
11219 Financial Centre Parkway, Suite 101
Little Rock, AR 72211
(501)553-9987 (501)
553-9986 FAX

Signature:_____

Date:_____

David Micheal Weed, M.D.

Email: aceweed2423@gmail.com

Phone: 501-553-9987

Research Affiliations

Offices

Preferred Research Partners, Inc.
11219 Financial Centre Parkway, Suite 320
Little Rock, AR 72211
(501) 553-9987
(501) 553-9986 FAX

Preferred Research Partners Arkansas Center for Sleep Medicine
11219 Financial Center Parkway, Suite 101
Little Rock, AR 72211
(501) 553-9987
(501) 553-9986 FAX

Education:

July 1995-June 1998: Arkansas Children's Hospital
Internship/Residency-Pediatrics

May 1995: University of Arkansas for Medical Sciences
Doctor of Medicine

May 1991: Hendrix College
Bachelor of Arts, Biology

Medical Licensure: State of Arkansas, 1998- Present

Board Certification: American Board of Pediatrics, 1998- Present

Organizations: American Board of Pediatrics, 1998- Present

Medical Staff Privileges:

- 1998-Present: Baptist Health Medical Center-Active
- 2000-Present: Saline Memorial Hospital- Courtesy

- 1998-Present: Arkansas Children's Hospital-Courtesy

Work Experience:

- Sub-Investigator: Preferred Research Partners, Inc.

December 2025-Present

- Pediatrician: Central Arkansas Pediatric Clinic

November 2000-Present

- Pediatrician: Little Rock Pediatric Clinic

June 1998-October 2000

Clinic Research Training:

Good Clinical Practice for Clinical Trials with Investigative Drugs and Medical Devices, December 2025

CITI Program, Human Research Curriculum Online Training
Basic Biomedical Course September 2011

Site Training Modules Online including:
GCP and Investigator Responsibilities
Clinical Monitoring and Study Conduct Overview
Patient Diversity
SAE Reporting
RDE and SBIR Learning Module
IntraLinks Training for Investigators/Sub-Investigators
By GlaxoSmithKline, October 2009

Human Subject Protection Training
HIPAA Research for Human Subjects Testing
By University of Arkansas for Medical Sciences, April 2007

Clinic Research Experience:

Primary Investigator:

- 2007-Wyeth 6096A1-3005, Stage 3 13 Valent Pneumococcal Vaccine Study
- 2006-Sanofi Pasteur GRC-28, Fluzone Influenza Virus Vaccine Study
- 2005-Mead Johnson project 3374-1, Dietary Management of Feeding Intolerance study
- 2012-GlaxoSmithKline Biologicals Study 115648, MMR vaccine 160 study

Sub-Investigator:

- 2008-GlaxoSmithKline 111751 Fluarix Influenza Vaccine study
- 2006-GlaxoSmithKline 444563-107531 VAQTA Hepatitis A Vaccine Study

- 2011-Pfizer ProtocolB1971009 Adolescent Meningoccal type B Vaccine in Adolescents Study
- Wyeth 6096A1-3011 13 Valent Pneumococcal Vaccine follow-up study
- 2021: AbbVie – Pediatric Migraine – 3110-305-002
- 2021: AbbVie -Pediatric Migraine – 3110-306-002
- 2023: AbbVie – Pediatric Episodic Migraine – M21-199
- 2023: AbbVie – Pediatric Episodic Migraine – M21-201
- 2023: Supernus – Pediatric ADHA - 812P401
- 2024: Axsome- Excessive Daytime Sleepiness with Shift Work Disorder – SOL-SWD-301
- 2024: AbbVie – Menstrual Migraine Prevention – M23-714
- 2024: Phathom- Eosinophilic Esophagitis – EoE-201
- 2024: Alto Neuroscience - Bipolar Depression - ALTO-100-211
- 2024: MindMed – Generalized Anxiety Disorder- MM120-301
- 2025: AbbVie – Pediatric Chronic Migraine ages 12-17 y/o- M23-712
- 2025: Alkermes- Idiopathic Hypersomnia – ALKS2680-203
- 2025: Alkermes – Narcolepsy – ALKS2680-301
- 2025: Mind Medicine, Inc. – Major Depressive Disorder (MDD) – MM123-310 (EMERGE)
- 2025: Atai Pharmaceuticals – Treatment Resistant Depression (TRD) – VLS-01-203
- 2025: Mirador Therapeutics, Inc. - Active Crohn's Disease or Active Ulcerative Colitis (ASCEND-IBD) – MT-100-201/PROBEUC/PROBECD
- 2025: Eli Lilly & Company - Moderately to Severely Active Ulcerative Colitis - I7J-MC-DSAG
- 2025: Axsome Therapeutics - Fibromyalgia - AXS-14-FM-301
- 2025: Sanofi-Aventis - Induction study Moderately to Severely Active Ulcerative Colitis- EFC18325
- 2025: Sanofi-Aventis - Induction study Moderately to Severely Active Crohn's Disease- EFC18326
- 2026: AbbVie - MDD - M25-987